{"id":"https://openalex.org/W7204016659","doi":null,"title":"Targeted-release budesonide for treating primary IgA nephropathy (review of TA937): a single technology appraisal","display_name":"Targeted-release budesonide for treating primary IgA nephropathy (review of TA937): a single technology appraisal","publication_year":2025,"publication_date":"2025-01-01","ids":{"openalex":"https://openalex.org/W7204016659"},"language":"en","primary_location":{"id":"pmh:oai:eprints.soton.ac.uk:513439","doi":null,"is_oa":false,"landing_page_url":"https://eprints.soton.ac.uk/id/eprint/513439/1/Budesonide_EAG_report_2026.pdf","pdf_url":"https://eprints.soton.ac.uk/id/eprint/513439/1/Budesonide_EAG_report_2026.pdf","source":{"id":"https://openalex.org/S4306401019","display_name":"ePrints Soton (University of Southampton)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I43439940","host_organization_name":"University of Southampton","host_organization_lineage":["https://openalex.org/I43439940"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Monograph"},"volume":null,"type":"book","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072527393","display_name":"Joanna Picot","orcid":"https://orcid.org/0000-0001-5987-996X","observed_orcids":["https://orcid.org/0000-0001-5987-996X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Picot, Joanna","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5137969400","display_name":"Joanne Lord","orcid":"https://orcid.org/0000-0003-1086-1624","observed_orcids":["https://orcid.org/0000-0003-1086-1624"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lord, Joanne","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009417975","display_name":"Karen Pickett","orcid":"https://orcid.org/0000-0002-8631-6465","observed_orcids":["https://orcid.org/0000-0002-8631-6465"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pickett, Karen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5039851179","display_name":"Bogdan Grigore","orcid":"https://orcid.org/0000-0003-4241-7595","observed_orcids":["https://orcid.org/0000-0003-4241-7595"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Grigore, Bogdan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.9375,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11029","display_name":"Renal Diseases and Glomerulopathies","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11029","display_name":"Renal Diseases and Glomerulopathies","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/primary-iga-nephropathy","display_name":"primary IgA nephropathy","score":0.8939999938011169},{"id":"https://openalex.org/keywords/clinical-effectiveness","display_name":"clinical effectiveness","score":0.6039999723434448},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8650000095367432},{"id":"https://openalex.org/keywords/nice-technology-appraisal","display_name":"NICE technology appraisal","score":0.6499999761581421},{"id":"https://openalex.org/keywords/proteinuria","display_name":"proteinuria","score":0.6570000052452087},{"id":"https://openalex.org/keywords/urine-protein-creatinine-ratio","display_name":"urine protein-to-creatinine ratio","score":0.7940000295639038},{"id":"https://openalex.org/keywords/glucocorticoid-therapy","display_name":"glucocorticoid therapy","score":0.7549999952316284}],"concepts":[{"id":"https://openalex.org/C2776136866","wikidata":"https://www.wikidata.org/wiki/Q422212","display_name":"Budesonide","level":3,"score":0.8366000056266785},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8015000224113464},{"id":"https://openalex.org/C2781184683","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Nephropathy","level":3,"score":0.620199978351593},{"id":"https://openalex.org/C2779256446","wikidata":"https://www.wikidata.org/wiki/Q33959","display_name":"Nice","level":2,"score":0.5771999955177307},{"id":"https://openalex.org/C2780026642","wikidata":"https://www.wikidata.org/wiki/Q40924","display_name":"Urine","level":2,"score":0.5730999708175659},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43810001015663147},{"id":"https://openalex.org/C2779102806","wikidata":"https://www.wikidata.org/wiki/Q79453","display_name":"Immunoglobulin A","level":4,"score":0.37860000133514404},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.37459999322891235},{"id":"https://openalex.org/C10146269","wikidata":"https://www.wikidata.org/wiki/Q185557","display_name":"Excretion","level":2,"score":0.36910000443458557},{"id":"https://openalex.org/C2780368995","wikidata":"https://www.wikidata.org/wiki/Q605006","display_name":"Glomerulonephritis","level":3,"score":0.36390000581741333},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.36340001225471497},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.35690000653266907},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3537999987602234},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.29019999504089355},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.28029999136924744},{"id":"https://openalex.org/C2779561371","wikidata":"https://www.wikidata.org/wiki/Q570197","display_name":"Proteinuria","level":3,"score":0.26669999957084656}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:eprints.soton.ac.uk:513439","doi":null,"is_oa":false,"landing_page_url":"https://eprints.soton.ac.uk/id/eprint/513439/1/Budesonide_EAG_report_2026.pdf","pdf_url":"https://eprints.soton.ac.uk/id/eprint/513439/1/Budesonide_EAG_report_2026.pdf","source":{"id":"https://openalex.org/S4306401019","display_name":"ePrints Soton (University of Southampton)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I43439940","host_organization_name":"University of Southampton","host_organization_lineage":["https://openalex.org/I43439940"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Monograph"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4409478310","https://openalex.org/W4400065426","https://openalex.org/W4400065417","https://openalex.org/W2775322345","https://openalex.org/W2600347335","https://openalex.org/W7141171460","https://openalex.org/W7147425890","https://openalex.org/W4406845017","https://openalex.org/W4200257655","https://openalex.org/W7222145849"],"abstract_inverted_index":{"This":[0],"report":[1],"is":[2],"a":[3,39],"critique":[4],"of":[5,22,57],"the":[6,16,53,58],"company\u2019s":[7],"submission":[8],"(CS)":[9],"to":[10],"NICE":[11],"from":[12],"Genus":[13],"Pharmaceuticals":[14],"on":[15],"clinical":[17],"effectiveness":[18,21],"and":[19,55],"cost":[20],"targeted":[23],"release":[24],"formulation":[25],"(TRF)-budesonide":[26],"budesonide":[27],"(Kinpeygo)":[28],"for":[29],"treating":[30],"adults":[31],"with":[32,38],"primary":[33],"immunoglobulin":[34],"A":[35],"(IgA)":[36],"nephropathy":[37],"urine":[40,46],"protein":[41],"excretion":[42],"\u22651.0":[43],"g/day":[44],"or":[45],"protein-to-creatinine":[47],"ratio":[48],"\u2265":[49],"0.8g/g.":[50],"It":[51],"identifies":[52],"strengths":[54],"weaknesses":[56],"CS.":[59]},"counts_by_year":[],"updated_date":"2026-09-17T22:18:28.273824","created_date":"2026-08-23T00:00:00"}